Suggested Reading
On Pancreatic Cancer
Abbott DE, Baker MS, Talamonti MS: Neoadjuvant therapy for pancreatic cancer: A current review. J Surg Oncol 101:315–320, 2010.
Abrams RA, Winter KA, Regine WF, et al: Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704: A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 82:809–816, 2012.
Altwegg R, Ychou M, Guillaumon V, et al: Second-line therapy for gemcitabine(Drug information on gemcitabine)-pretreated advanced or metastatic pancreatic cancer. World J Gastoenterol 18:1357–1364, 2012.
Aschebrook-Kilfoy B, Cross AJ, Stolzenberg-Solomon RZ, et al: Pancreatic cancer and exposure to dietary nitrate and nitrite in the NIH-AARP Diet and Health Study. Am J Epidemiol 174:305–315, 2011.
Ben-Josef E, Griffith K, Francis IR, et al: Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol 27(15s): abstract 4602, 2009.
Berger AC, Garcia M, Hoffman JP, et al: Postresection CA19-9 predicts overal survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 26:2918–5922, 2008.
Bilimoria KY, Bentrem DJ, Ko CY, et al: Multimodality therapy for pancreatic cancer in the US: Utilization, outcomes, and the effect of hospital volume. Cancer 110:1227–1234, 2007.
Colucci G, Labianca R, Di Costanzo F, et al: Randomized phase III trial of gemcitabine plus cisplatin(Drug information on cisplatin) compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study. J Clin Oncol 28:1645–1641, 2010.
Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825, 2011.
Costello E, Greenhalf W, Neoptolemos JP: New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9:435–444, 2012.
Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine(Drug information on capecitabine) in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518, 2009.
Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212–2217, 2007.
Katz MH, Varadhachary GR, Fleming JB, et al: Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17:1794–1801, 2010.
Kindler HL, Niedzwiecki D, Hollis D, et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab(Drug information on bevacizumab) (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25(18S): abstract 4508, 2007.
Loehrer PJ Sr, Feng Y, Cardenes H, et al: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112, 2011.
Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966, 2007.
Neoptolemos JP, Moore MJ, Cox TF, et al: Effect of adjuvant chemotherapy with fluorouracil(Drug information on fluorouracil) plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary aAdenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA 308:147–156, 2012.
Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304:1073–1081, 2010.
Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267–277, 2007.
Pelzer U, Kubica K, Stieler J, et al: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26(15S): abstract 4508, 2008.
Philip PA, Benedetti J, Fenoglio-Preiser C, et al: Phase III study of gemcitabine [G] plus cetuximab(Drug information on cetuximab) [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25:5777–5784, 2007.
Philip PA, Mooney M, Jaffe D, et al: Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27:5660–5669, 2009.
Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin(Drug information on oxaliplatin) versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785, 2009.
Regine WF, Winter KA, Abrams R, et al: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18:1319–1326, 2011.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011. CA Cancer J Clin 61: 212–236, 2011.
Ujiki MB, Talamonti MS: Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol 34:311–320, 2007.
Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231–2237, 2009.
Wong GY, Schroeder DR, Carns PE, et al: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA 3:1092–1099, 2004.
On Neuroendocrine GI Tumors
Bomanji JB, Papathanasiou ND: 111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging 39(Suppl):S113–S125, 2012.
Chan JA, Stuart K, Earle CC, et al: Prospective study of bevacizumab plus temozolomide(Drug information on temozolomide) in patients with advanced neuroendocrine tumors. J Clin Oncol 30:2963–2968, 2012.
Cwikla JB, Sankowski A, Seklecka N, et al: Efficacy of radionuclide treatment DOTATATE γ-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETS): A phase II study. Ann Oncol 21:787–794, 2010.
Ho AS, Picus J, Darcy MD, et al: Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol 188:1201–1207, 2007.
Hsu C, Rashid A, Xing Y, et al: Varying malignant potential of appendiceal neuroendocrine tumors: Importance of histologic subtype. J Surg Oncol 107:136–143, 2013.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al: Radiolabeled somatostatin(Drug information on somatostatin) analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762, 2005.
Kvols L, Oberg KE, O’Dorisio T, et al: Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide(Drug information on octreotide) LAR: results from a phase II study. Endocr Relat Cancer 19:657–666, 2012.
Mazzaglia PJ, Berber E, Milas M, et al: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival. Surgery 142:10–19, 2007.
Musunuru S, Chen H, Rajpal S, et al: Metastatic neuroendocrine hepatic tumors: Resection improves survival. Arch Surg 141:1000–1004, 2006.
Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973, 2004.
Teh SH, Deveney C, Sheppard BC: Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: Is it justifiable? Am J Surg 193:610–613, 2007.
On Adrenal Neoplasms
Dreicer R: Systemic therapy for advanced adrenal cancer. J Surg Oncol 106:643–646, 2012.
Fassnacht M, Terzolo M, Allolio B, et al: Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189–2197, 2012.
Jossart GH, Burpee SE, Gagner M: Surgery of the adrenal glands. Endocrinol Metab Clin North Am 29:57–68, 2000.
Lehmann T, Wrzesinski T: The molecular basis of adrenocortical cancer. Cancer Genet 205:131–137, 2012.
Libè R, Fratticci A, Bertherat J: Adrenocortical cancer: Pathophysiology and clinical management. Endocr Relat Cancer 14:13–28, 2007.
Milgrom SA, Goodman KA: The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. J Surg Oncol 106:647–650, 2012.
Pua BB, Solomon SB: Ablative therapies in adrenal tumors: Primary and metastatic. J Surg Oncol 106:626–631, 2012.
Terzolo M, Angeli A, Fassnacht M, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372–2380, 2007.
On Carcinoids
Goede AC, Winslet MC: Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Dis 5:123–128, 2003.
Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652–1659, 2010.
Kolby L, Persson G, Franzen S, et al: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687–693, 2003.
Moller JE, Connolly HM, Rubin J, et al: Factors associated with progression of carcinoid heart disease. N Engl J Med 348:1005–1015, 2003.
Schell SR, Camp ER, Caridi JG, et al: Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664–670, 2002.
van der Horst-Schrivers AN, Wymenga AN, de Vries EG: Carcinoid heart disease. N Engl J Med 348:2359–2361, 2003.
On Pheochromocytomas
Baghai M, Thompson GB, Young WF Jr, et al: Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: A role for laparoscopic and cortical-sparing surgery. Arch Surg 137:682–689, 2002.
Burnichon N, Cascon A, Schiavi F, et al: MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18:2828–2837, 2012.
Safford SD, Coleman RE, Gockerman JP, et al: Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134:956–962, 2003.
Zendron L, Fehrenbach J, Taverna C, et al: Pitfalls in the diagnosis of phaeochromocytoma. Br Med J 13:629–630, 2004.
